Horn Howard sold $111K of RARE
Horn Howard (Chief Financial Officer) sold 4,653 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $23.77 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a mechanical disclosure rather than a fundamental update; absent other catalysts, it is unlikely to change valuation drivers.
Market read
Insider selling disclosure for RARE with limited incremental trading signal due to 10b5-1 pre-arrangement and lack of new business information.
What to watch
The filing does not reveal the broader context (e.g., total insider activity over prior months, tax-related selling, or diversification needs).
Background
SEC Form 4 reports insider transactions; this one is an officer/direct sale under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Ultragenyx CFO Horn Howard sold 4,653 shares in an open-market transaction at $23.77 on a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any reaction would be muted unless paired with other company-specific news.
Form 4 insider sales are typically informational but not necessarily bearish, especially when explicitly executed under a pre-arranged 10b5-1 plan and without accompanying guidance/trial/contract updates.
Market effects
Minimal; single-company Form 4 insider sale does not reset sector expectations.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with management confidence gaps; traders may still interpret repeated insider selling as a risk signal if it accelerates.
Key entities
- insiderHorn Howard
Ultragenyx CFO who sold 4,653 shares under a pre-arranged 10b5-1 plan.
- issuerUltragenyx Pharmaceutical Inc.
RARE, the company whose shares were sold by its CFO.
